ArticleMolecular oncology2024
Strategies to decrease inequalities in cancer therapeutics, care and prevention: Proceedings on a conference organized by the Pontifical Academy of Sciences and the European Academy of Cancer Sciences, Vatican City, February 23-24, 2023.
Article in Molecular oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- AI-driven nanomedicine for cancer theranostics.Molecular cancer · 2026Review
- Developing evidence-based, cost-effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities.Molecular oncology · 2026Article
- Access to molecular diagnostics for CNS tumors through international outsourcing: experience from Jordan.Frontiers in oncology · 2026Article
- Unlocking the Potential of Polysaccharides for the Treatment of Lung Cancer.Anti-cancer agents in medicinal chemistry · 2026Review
- Strategies to reduce the cancer burden and improve access to effective and affordable cancer interventions in Europe.Molecular oncology · 2025Article
- "Carnosine-Niosomal Delivery System for Targeted Cancer Therapy".Cell biochemistry and biophysics · 2025Review
- Describing the Core Attributes and Impact of Comprehensive Cancer Centers Internationally: A Chronological Scoping Review.Cancers · 2025Review
- Nanotechnology-Enhanced Extracellular Vesicles -Based Chipsets in Early Cancer Detection and Theranostics.International journal of nanomedicine · 2025Review
- Understanding the Landscape of Cancer Care in Europe: Evaluating Clinical and Comprehensive Cancer Centers.Healthcare (Basel, Switzerland) · 2024Article
- Perceptions of Cancer Through the Ages-From Hippocratic Oncology to Precision Cancer Medicine.Biomolecules · 2024Review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions.Journal of clinical medicine · 2024Review
- Academia and society should join forces to make anti-cancer treatments more affordable.Molecular oncology · 2024Review
- From the creation of the European research area in 2000 to a Mission on cancer in Europe in 2021-lessons learned and implications.Molecular oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors.
Funding
Abstract
Analyses of inequalities related to prevention and cancer therapeutics/care show disparities between countries with different economic standing, and within countries with high Gross Domestic Product. The development of basic technological and biological research provides clinical and prevention opportunities that make their implementation into healthcare systems more complex, mainly due to the growth of Personalized/Precision Cancer Medicine (PCM). Initiatives like the USA-Cancer Moonshot and the EU-Mission on Cancer and Europe's Beating Cancer Plan are initiated to boost cancer prevention and therapeutics/care innovation and to mitigate present inequalities. The conference organized by the Pontifical Academy of Sciences in collaboration with the European Academy of Cancer Sciences discussed the inequality problem, dependent on the economic status of a country, the increasing demands for infrastructure supportive of innovative research and its implementation in healthcare and prevention programs. Establishing translational research defined as a coherent cancer research continuum is still a challenge. Research has to cover the entire continuum from basic to outcomes research for clinical and prevention modalities. Comprehensive Cancer Centres (CCCs) are of critical importance for integrating research innovations to preclinical and clinical research, as for ensuring state-of-the-art patient care within healthcare systems. International collaborative networks between CCCs are necessary to reach the critical mass of infrastructures and patients for PCM research, and for introducing prevention modalities and new treatments effectively. Outcomes and health economics research are required to assess the cost-effectiveness of new interventions, currently a missing element in the research portfolio. Data sharing and critical mass are essential for innovative research to develop PCM. Despite advances in cancer research, cancer incidence and prevalence is growing. Making cancer research infrastructures accessible for all patients, considering the increasing inequalities, requires science policy actions incentivizing research aimed at prevention and cancer therapeutics/care with an increased focus on patients' needs and cost-effective healthcare.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.